|1.||Redman, Rebecca: 11 articles (11/2015 - 01/2009)|
|2.||Nicolau, David P: 10 articles (01/2014 - 07/2008)|
|3.||Kaniga, Koné: 9 articles (04/2013 - 06/2005)|
|4.||Cirillo, Iolanda: 6 articles (11/2015 - 03/2011)|
|5.||Friedland, Ian: 6 articles (05/2010 - 04/2008)|
|6.||Lee, Michael: 5 articles (04/2013 - 04/2008)|
|7.||Vaccaro, Nicole: 4 articles (08/2015 - 03/2011)|
|8.||Mundy, Linda M: 4 articles (11/2013 - 12/2010)|
|9.||Nathwani, Dilip: 4 articles (03/2010 - 04/2008)|
|10.||Merchant, Sanjay: 4 articles (03/2010 - 04/2008)|
05/01/2010 - "Doripenem and comparators were highly clinically effective in infections caused by Enterobacteriaceae, irrespective of their ESBL statuses. "
06/01/2011 - "These results suggest that doripenem treatment is effective against chronic airway infection with P. "
07/01/2006 - "The combination of doripenem and an aminoglycoside may be an effective treatment of infections caused by P. "
12/01/2011 - "In our limited sample size, doripenem was safe and effective against various types of infections in a general inpatient population with similar bacterial susceptibilities to other cabapenems. "
04/01/2011 - "Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: A multicenter trial."
08/01/2013 - "A pharmacokinetic (PK) analysis of a 1-h intravenous (i.v.) dose of 500 mg doripenem in ten clinically ill, elderly patients with nosocomial pneumonia (NP) was conducted. "
08/01/2013 - "Pharmacokinetic analysis of doripenem in elderly patients with nosocomial pneumonia."
06/01/2013 - "Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients."
03/01/2012 - "Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia."
02/01/2011 - "She developed pneumonia and was started on doripenem 500mg IV every 8 hours. "
|3.||Urinary Tract Infections (Urinary Tract Infection)
12/01/2009 - "Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. "
07/01/2008 - "In this article, you'll learn about eight new drugs, including: doripenem, an antibiotic for complicated intra-abdominal and urinary tract infections. "
04/01/2002 - "The antibacterial activity of S-4661, a new parenteral carbapenem antibiotic, was assessed against the major urological pathogens isolated from patients with complicated urinary tract infections. "
04/01/2002 - "In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections."
12/01/2010 - "Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis."
06/01/2013 - "For mouse septicemia, doripenem (100 mg/kg) was ≥90% effective in preventing death in all four isolates. "
01/01/2014 - "The aim of this study was to establish the impact of continuous renal replacement therapy (CRRT) slow low-efficiency dialysis (SLED) on doripenem serum concentrations in a population of intensive-therapy patients with life-threatening infections and severe sepsis. "
08/01/2012 - "Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases."
01/01/2014 - "The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis."
01/01/2008 - "Doripenem is indicated in Japan for use as a single agent in intra-abdominal infections (IAIs), lower respiratory tract infections (including nosocomial pneumonia), complicated urinary tract infections (cUTIs) and a variety of other bacterial infections, such as complicated skin and skin structure infections (cSSSIs), obstetric and gynaecological infections, serious ear, nose and throat infections, sepsis and endocarditis, dental and oral surgical infection, and ophthalmic infection caused by various susceptible strains of Gram-negative, Gram-positive or anaerobic bacteria. "
|5.||Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated)
11/01/2012 - "The aim of this study was to assess the population pharmacokinetics and probabilities of target attainment (PTAs) of doripenem in patients with ventilator-associated pneumonia, comparing administration by 1-h and 4-h infusion. "
01/01/2010 - "Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators."
08/15/2009 - "The reduced medical resource use achieved with use of doripenem for treatment of ventilator-associated pneumonia may provide not only clinical benefits to patients but also economic benefits to hospitals and health care systems."
04/01/2008 - "Doripenem is an investigational carbapenem with broad-spectrum activity against gram-negative and gram-positive pathogens, including multidrug-resistant strains, commonly responsible for ventilator-associated pneumonia (VAP). "
08/15/2009 - "The topics addressed include antimicrobial resistance and the available therapeutic options against gram-negative pathogens, the in vitro activity of doripenem, the efficacy and safety of intravenous infusion of doripenem, and the clinical and economic consequences of ventilator-associated pneumonia. "
|3.||Carbapenems (Carbapenem Antibiotics)
|8.||imipenem drug combination cilastatin (Primaxin)
|1.||Renal Replacement Therapy (Therapies, Renal Replacement)
|3.||Mechanical Ventilators (Ventilator)
|4.||Renal Dialysis (Hemodialysis)